In the field of radiopharmacy, PSI's infrastructure covers the entire spectrum. In particular, PSI researchers are tackling very small tumours distributed throughout the body. These cannot be treated with the usual radiotherapy techniques. New medically applicable radionuclides have, however, been produced with the help of the proton accelerators and the neutron source SINQ at PSI. When combined for therapy with special biomolecules – so-called antibodies, therapeutic molecules can be formed to selectively and specifically detect tumour cells. These are then labelled with a radioactive isotope. Its radiation can be localized with imaging techniques such as SPECT or PET, which enables the diagnosis of tumours and their metastases. Moreover, it can be dosed so that it also destroys the tumour cells. Several such radioactive substances have been developed at PSI. They are currently being tested in clinical trials, in close cooperation with universities, clinics and the pharmaceutical industry. PSI also supplies local hospitals with radiopharmaceuticals if required.